Vernalis PLC Vernalis plc - Board Change (9499X)
16 Agosto 2018 - 8:01AM
UK Regulatory
TIDMVER
RNS Number : 9499X
Vernalis PLC
16 August 2018
16 August 2018
LSE: VER
Vernalis plc ("Vernalis" or the "Company")
Board Change
Vernalis plc today announces that Dr Ian Gilham has decided to
step down from his role as a Non-Executive Director and Chair of
the Remuneration Committee of Vernalis plc with immediate effect
rather than continue on the Board until completion of the proposed
acquisition of Vernalis plc by Ligand Holdings UK Ltd.
Carol Ferguson, who is a member of the Remuneration Committee,
will take the role as Chair of that Committee.
Dr Peter Fellner, Chairman of the Board of Vernalis commented
"We would like to thank Ian for his contributions to the Board over
the last three years and the Board wishes him well in his future
endeavours."
Enquiries:
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Canaccord Genuity Limited (Nominated
Adviser and Broker): +44 (0) 20 7523 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
Evercore (Financial Adviser): +44 (0) 20 7653 6000
Julian Oakley
Alan Beirne
Notes to Editors
Vernalis is a revenue generating, pharmaceutical company with
significant expertise in drug development. The Group has two
approved products: Moxatag(R) , a once-daily formulation of the
antibiotic, amoxicillin, indicated for the treatment of tonsillitis
and/or pharyngitis secondary to Streptococcus pyogenes in adults
and pediatric patients 12 years and older; and frovatriptan for the
acute treatment of migraine. Vernalis has also nine programmes in
its NCE development pipeline in addition to significant expertise
in fragment and structure based drug discovery which it leverages
to enter into collaborations with larger pharmaceutical companies.
The Company's technologies, capabilities and products have been
endorsed over the last five years by collaborations with leading
pharmaceutical companies, including Asahi Kasei Pharma, Biogen
Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini,
Novartis and Servier.
For further information about Vernalis, please visit
www.vernalis.com
Rule 26.1 disclosures
A copy of this announcement will be made available (subject to
certain restrictions relating to persons resident in restricted
jurisdictions) on Vernalis' website at www.vernalis.com by no later
than 12 noon (London time) on the business day following the
release of this announcement in accordance with Rule 26.1 of the
City Code on Takeovers and Mergers. The content of the website
referred to in this announcement is not incorporated into and does
not form part of this announcement.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPAMRTMBIBBMP
(END) Dow Jones Newswires
August 16, 2018 02:01 ET (06:01 GMT)
Grafico Azioni Vernalis (LSE:VER)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Vernalis (LSE:VER)
Storico
Da Mag 2023 a Mag 2024